All In Biotech

Drug Trial Radar · NCT04524871

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 518 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

518

Planned (sponsor's estimate)

Start

Nov 1, 2020

Primary completion

Jul 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Adagene Inc; Tempest Therapeutics; NiKang Therapeutics, Inc.; Immune-Onc Therapeutics
First posted
Aug 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.

Conditions

  • Advanced Liver Cancers

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.

  • Bevacizumab 15 mg/kgDrug

    Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.

  • TiragolumabDrug

    Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

  • TocilizumabDrug

    Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.

  • TPST-1120Drug

    TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.

  • Tobemstomig 2100 mgDrug

    Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.

  • Bevacizumab 10 mg/kgDrug

    Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.

  • Tobemstomig 600 mgDrug

    Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

  • Tobemstomig 1200 mgDrug

    Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.

  • ADG126Drug

    ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).

  • IO-108 1800 mgDrug

    IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.

  • NKT2152Drug

    NKT2152 will be administered by mouth.

  • IO-108 1200 mgDrug

    IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From randomization until disease progression or loss of clinical benefit (up to approximately 7-9 years)

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • UC Irvine Medical Center

    Costa Mesa, California

  • City of Hope

    Duarte, California

  • UC Irvine Medical Center

    Orange, California

  • University of California San Diego Medical Center

    San Diego, California

  • University of California San Francisco Cancer Center

    San Francisco, California

  • UCLA Center for East

    Santa Monica, California

  • Cherry Creek Medical Center

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital

    Highlands Ranch, Colorado

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of Kentucky - Markey Cancer Center

    Lexington, Kentucky

  • Oregon Health & Science University

    Portland, Oregon

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Parkland Health & Hospital System

    Dallas, Texas

  • The University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas

  • Beijing Cancer Hospital

    Beijing, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • Centre Georges Francois Leclerc

    Dijon, France

  • CHU Hôpitaux de Marseille

    Marseille, France

  • Centre Eugène Marquis

    Rennes, France

  • Gustave Roussy

    Villejuif, France

  • Rambam Medical Center

    Haifa, Israel

  • Hadassah University Medical Center

    Jerusalem, Israel

  • Davidof Center - Rabin Medical Center

    Petah Tikva, Israel

  • Sourasky Medical Centre

    Tel Aviv, Israel

  • Auckland City Hospital

    Auckland, New Zealand

  • CHA Bundang Medical Center

    Gyeonggi-do, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.